 |
|
Adolescents With Depression
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: In interpreting the TADS results,1 the central issue is the benefit-to-risk ratio, which can be determined by considering the number needed to treat (NNT), the number needed to harm (NNH), and the number needed to prevent.2 In this study, a categorical positive response was achieved in 71.0% of participants treated with fluoxetine in combination with CBT; in 60.6% with fluoxetine alone; in 43.2% with CBT alone; and in 34.8% with placebo. Based on these outcomes, the NNT is 3.9 for fluoxetine alone compared with placebo and 3.7 for drug vs no drug. I believe that these represent low NNTs (high benefit) that are clinically meaningful.
The TADS Team reported suicide-related adverse events in 6.9% of children taking fluoxetine and in 4.0% of children who did not take fluoxetine; this corresponds to a NNH of 34. Likewise, TADS reported suicide attempts in 6 (2.78%) of 216 adolescents . . . [Full Text of this Article]
Bernard J. Carroll, MB, BS, PhD
bcarroll@redshift.com
Pacific Behavioral Research Foundation
Carmel, Calif
RELATED ARTICLES
Adolescents With Depression
David Antonuccio and David Burns
JAMA. 2004;292(21):2577.
EXTRACT
| FULL TEXT
Adolescents With Depression
Arthur Rifkin and William Rifkin
JAMA. 2004;292(21):2577-2578.
EXTRACT
| FULL TEXT
Adolescents With Depression
Jeffrey A. Bridge and David A. Brent
JAMA. 2004;292(21):2578.
EXTRACT
| FULL TEXT
Adolescents With Depression—Reply
John S. March
JAMA. 2004;292(21):2578-2579.
EXTRACT
| FULL TEXT
Fluoxetine, Cognitive-Behavioral Therapy, and Their Combination for Adolescents With Depression: Treatment for Adolescents With Depression Study (TADS) Randomized Controlled Trial
Treatment for Adolescents With Depression Study Team
JAMA. 2004;292(7):807-820.
ABSTRACT
| FULL TEXT
|
